Robert W. Baird upgrades Henry Schein (HSIC) to a Buy
In a report released today, Jeff Johnson from Robert W. Baird upgraded Henry Schein to a Buy, with a price target of $100.00.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
According to TipRanks, Johnson is a 5-star analyst with an average return of 10.8% and a 50.40% success rate. Johnson covers the Healthcare sector, focusing on stocks such as Envista Holdings, Dexcom, and Align Tech.
Henry Schein has an analyst consensus of Moderate Buy, with a price target consensus of $88.80.
Based on Henry Schein’s latest earnings release for the quarter ending September 27, the company reported a quarterly revenue of $3.34 billion and a net profit of $101 million. In comparison, last year the company earned a revenue of $3.17 billion and had a net profit of $99 million
Read More on HSIC:
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.